

Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole

ANDRÉ J. A. M. VAN DER VEN¹, TOM B. VREE², ELEONORA W. J. VAN EWIK-BENEKEN KOLMER², PETER P. KOOPMANS¹ & JOS W. M. VAN DER MEER¹

¹Department of General Internal Medicine, Division of Internal Medicine and ²Department of Clinical Pharmacy, Academic Hospital, Nijmegen St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands

- 1 The urinary excretion of sulphamethoxazole and its metabolites was compared between healthy volunteers and HIV-seropositive patients in order to get a better understanding of why HIV seropositives are more predisposed to idiosyncratic toxicity of sulphonamides.
- 2 A single 800 mg oral dose of sulphamethoxazole was administered to seven healthy volunteers and seven asymptomatic HIV seropositives without previous use of sulphonamides.
- 3 Urine was collected for 4 days and drug analysis was by h.p.l.c.
- 4 No difference was observed between seropositive and seronegative individuals in the urinary recovery of sulphamethoxazole, *N*4-acetyl-, 5-hydroxy-, *N*4-acetyl-5-hydroxy-sulphamethoxazole and the *N*1-glucuronide conjugate. However the recovery of the hydroxylamine metabolite of sulphamethoxazole was significantly lower in the HIV seropositives (0.50 ± 0.51 vs $2.23 \pm 0.85\%$; 95% CI on the difference, -0.90 to -2.55 ; $P = 0.0006$).
- 5 Sulphamethoxazole hydroxylamine may be a factor in the susceptibility of HIV infected individuals to sulphonamides.

Keywords sulphamethoxazole pharmacokinetics sulphamethoxazole hydroxylamine drug adverse reaction HIV infection metabolism

Introduction

The frequency of adverse reactions to sulphonamides is much higher in HIV-seropositive individuals (6–80%) as compared with seronegative individuals (< 5%) [1–10]. It has been postulated that the reactive hydroxylamine metabolites of sulphonamides mediate these adverse reactions [11–13]. Toxicity is more likely to occur when the scavenging system for such reactive intermediates is deficient, i.e. glutathione deficiency in HIV infection [14–15]. *In vitro* studies have confirmed the relationship between increased toxicity of hydroxylamines towards lymphocytes of HIV-infected individuals and decreased glutathione concentrations in these cells [16].

The known metabolism (Figure 1) of sulphamethoxazole (SMX) involves acetylation leading to

*N*4-acetylsulphamethoxazole (*N*4-SMX), glucuronidation leading to *N*1-glucuronide conjugate (SMX-gluc) and oxidation [17–18]. The latter reactions are cytochrome P450 mediated [19] and take place at the C5 carbon atom, leading to 5-hydroxysulphamethoxazole (5OH-SMX) and *N*4-acetyl-5-hydroxy-sulphamethoxazole (*N*4-5OH-SMX), as well as at the *N*4 nitrogen atom leading to the unstable and toxic hydroxylamine metabolite (NOH-SMX) [20]. Hydroxylamines can undergo auto-oxidation to nitroso derivatives, a process prevented by glutathione.

We have previously reported the formation and elimination of SMX and all its known metabolites in healthy volunteers after administration of a single oral dose [21, 22]. We now report a similar study in

Correspondence: Dr André J. A. M. van der Ven, Department of General Internal Medicine, Division of Internal Medicine, Academic Hospital, Nijmegen St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands




Figure 1 Metabolism of sulphamethoxazole.

HIV-seropositive individuals in order to obtain more insight into the reasons why HIV seropositives are more predisposed to sulphonamide toxicity.

Methods

Subjects

Seven healthy volunteers (4 M, 3 F) aged between 23 and 50 years (mean 34 years) and seven HIV-seropositive volunteers participated in the study after approval of the Ethics Committee of Academic Hospital, Nijmegen. Routine biochemical assessments (including liver function) were within normal limits in all participants. The HIV-seropositive individuals (6 M, 1 F) were aged between 31 and 53 years (mean 39 years), were all asymptomatic, CDC class II, had a mean CD 4 count of $294 \pm 111/\text{mm}^3$ (range 140–480/ mm^3) and were without previous sulphonamide treatment after seroconversion.

Written informed consent was obtained from all participants. An 800 mg dose of sulphamethoxazole was administered orally in two gelatine capsules after an overnight fast. Two volunteers participated twice in the study in order to determine the reproducibility.

Sampling procedures

Blood samples were only taken from the healthy volunteers while urine samples were collected from both healthy volunteers and seropositives. Blood samples were obtained by fingertip puncture at 1, 2, 4, 6, 8, 10, 12, 24, 32, 36, and 48 h after drug administration. Plasma was separated immediately by centrifugation and stored at -20°C until analysis. Urine was collected over 96 h and three 5 ml aliquots were stored immediately at -20°C until analysis.

Sample treatment and drug analysis has been described in detail elsewhere [18].

Data analysis

Curve fitting of the plasma concentration- and renal excretion rate-time curves was carried out using a one compartment model with first order drug absorption ($r^2 < 0.98$) and pharmacokinetic parameters calculated using the Medi-ware® computer program [23].

The following parameters for *N*₄-SMX were calculated from the renal excretion rate-time profiles: elimination half-life ($t_{1/2,z}$), lag time (t_{lag}), time at which maximum excretion occurs (t_{max}), mean residence time ($\text{MRT} = V_{ss}/\text{CL} + 1/k_a + t_{lag}$), maximal renal excretion rate (U_{max}) and area under renal excretion

rate-time curve (AUC_u). AUC values were calculated using the linear trapezoidal rule with extrapolation to infinity.

In addition, $t_{1/2,z}$, t_{lag} , t_{max} and MRT were calculated for *N4*-SMX in plasma of healthy volunteers. $t_{1/2,z}$ was also estimated for NOH-SMX in plasma of healthy volunteers.

Statistics

95% confidence intervals on the differences of the means for unpaired (or paired when appropriate) observations were determined.

Results

The urinary recoveries of parent drug and metabolites were similar in both HIV-negative and HIV-positive subjects with the exception of the urinary excretion of NOH-SMX (see Table 1). The recovery of the

hydroxylamine metabolite of sulphamethoxazole was lower in HIV seropositives compared with healthy volunteers. The results of the two volunteers that participated in the study twice were similar.

For healthy volunteers the value (mean \pm 1 s.d. or median) of $t_{1/2}$, t_{max} , t_{lag} and MRT of *N4*-SMX calculated from the renal excretion rate-time profiles was 10.34 ± 1.42 h, 7.48 h, 0.34 ± 0.24 h and 19.40 ± 2.85 h respectively. The 95% confidence interval on the difference between the mean $t_{1/2}$, t_{max} , t_{lag} and MRT for *N4*-SMX calculated from the plasma metabolite concentration-time curves [22] and the renal excretion rate-time profiles were -0.51 to 2.87, -1.93 to 0.28, -0.44 to 0.76 and -0.89 to 2.44 respectively. Also the half-lives of *N4*-SMX and NOH-SMX in urine of healthy volunteers did not differ statistically ($P > 0.8$).

The pharmacokinetic parameters of *N4*-SMX in urine of healthy volunteers and HIV seropositives are listed in Table 2. Only the maximum excretion rate (U_{max}) of *N4*-SMX was significantly different in the two groups.

Table 1 Urinary recovery of sulphamethoxazole and its metabolites in seven healthy volunteers and seven HIV seropositives (expressed as percentage of the dose of sulphamethoxazole) after an oral dose of 800 mg sulphamethoxazole. Mean values \pm s.d. and 95% confidence intervals on differences between the mean values are given

	HIV seropositives (n = 7)	Healthy volunteers (n = 7)	95% CI	P
<i>N4</i> -SMX	50.27 \pm 8.63	43.21 \pm 6.25	-1.72 to 15.84	0.11
SMX	12.66 \pm 5.02	14.64 \pm 3.80	-7.18 to 3.20	0.42
<i>N1</i> -gluc-SMX	12.68 \pm 2.68	9.66 \pm 3.00	-0.29 to 6.33	0.07
<i>N4</i> -5OH-SMX	5.50 \pm 1.59	5.20 \pm 1.07	-1.28 to 1.88	0.68
5OH-SMX	3.64 \pm 1.94	2.70 \pm 1.19	-2.82 to 0.94	0.29
NOH-SMX	0.50 \pm 0.51	2.23 \pm 0.85	-0.90 to -2.55	0.0006
Total	83.9 \pm 6.23	78.25 \pm 5.23	-1.04 to 12.35	0.09

N4-acetylsulphamethoxazole (*N4*-SMX), sulphamethoxazole (SMX), *N1*-glucuronide conjugate (SMX-gluc), *N4*-acetyl-5-hydroxy-sulphamethoxazole (*N4*-5OH-SMX), 5-hydroxysulphamethoxazole (5OH-SMX) and sulphamethoxazole hydroxylamine (NOH-SMX).

Table 2 Pharmacokinetic parameters of *N4*-acetylsulphamethoxazole in urine of HIV seropositives and healthy volunteers after an oral dose of 800 mg sulphamethoxazole. Mean values \pm s.d. (t_{max} is median and range) are given as well as 95% confidence intervals (CI) on the differences between the mean values

	HIV seropositives (n = 7)	Healthy volunteers (n = 7)	95% CI	P
$t_{1/2,z}$ (h)	8.69 \pm 2.12	10.34 \pm 1.42	-3.74 to 0.46	0.11
t_{max} (h)	7.48* (5.60-8.57)	6.56* (5.96-11.06)	-2.05 to 1.41	0.69
t_{lag} (h)	0.57 \pm 0.48	0.34 \pm 0.24	-0.22 to 0.67	0.29
MRT (h)	17.43 \pm 2.11	19.40 \pm 2.85	-4.89 to 0.96	0.17
U_{max} (mg h ⁻¹)	23.28 \pm 6.16	17.16 \pm 3.27	0.37 to 11.87	0.04
AUC_u (mg)	478 \pm 90	405 \pm 53	-12.55 to 158.83	0.09

$t_{1/2,z}$ = half-life, t_{max} = time at which maximum excretion occurs, *expressed as median (range), t_{lag} = lag time, MRT = mean residence time, U_{max} = maximum renal excretion rate, AUC_u = area under renal excretion rate-time curve.

Discussion

The formation and elimination of sulphamethoxazole and all its known metabolites in healthy volunteers and HIV-seropositive individuals were compared to understand better the predisposition of HIV seropositives to sulphonamide toxicity. Only the urinary recovery of sulphamethoxazole hydroxylamine differed between healthy volunteers and HIV-seropositive individuals. No difference was observed in urinary recovery of SMX, *N*4-SMX, SMX-gluc, *N*4-5OH-SMX and 5OH-SMX. The formation of the latter metabolite is, like NOH-SMX and probably *N*4-5OH-SMX, catalysed by cytochrome P450 [20]. These findings suggest that there is no difference in oxidation, acetylation and glucuronidation of SMX in healthy volunteers and HIV-seropositive individuals. The reduced urinary recovery of the hydroxylamine metabolite may be explained by secondary metabolism of an unstable compound that can be further oxidized to reactive metabolites [20]. This process is

prevented e.g. by glutathione. Glutathione protects cells from the toxicity of NOH-SMX largely by preventing its further oxidation to reactive metabolites [20]. These results suggest that the formation of the hydroxylamine metabolite is similar in both groups but that only HIV seropositives further metabolize NOH-SMX. This could explain the increased frequency of adverse reactions and the diminished recovery of NOH-SMX in this group of individuals.

The renal excretion rate-time profile of *N*4-SMX was taken as the main parameter for comparison of the metabolic and kinetic behaviour of SMX in healthy volunteers and HIV seropositives. Although the maximum renal excretion rate (U_{\max}) was different, other parameters like t_{\max} , t_{lag} , MRT and AUC_u were not. It may therefore be concluded that the renal excretion of *N*4-SMX does not differ between seropositives and healthy volunteers.

References

- 1 Van der Ven AJAM, Koopmans PP, Vree TB, van der Meer JWM. Adverse reactions to co-trimoxazole in HIV infection. *Lancet* 1991; **338**: 431–433.
- 2 Kovacs JA, Hiemans JW, Macher AM, et al. *Pneumocystis carinii* pneumonia. A comparison between patients with the Acquired Immunodeficiency Syndrome and patients with other immunodeficiencies. *Ann Int Med* 1984; **100**: 663–671.
- 3 Jaffe HS, Abrams DI, Amman AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in the treatment of Aids-associated *Pneumocystis carinii* pneumonia in homosexual men. *Lancet* 1983; **ii**: 1109–1111.
- 4 Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the Acquired Immunodeficiency Syndrome. *Ann Int Med* 1984; **100**: 495–499.
- 5 Lee BL, Medina II, Benowitz NL, Jacob P, Wofsy CB, Mills J. Dapsone, trimethoprim and sulfamethoxazole plasma levels during treatment of *Pneumocystis carinii* pneumonia in patients with the Acquired Immunodeficiency Syndrome (Aids). Evidence of drug interactions. *Ann Int Med* 1989; **110**: 606–611.
- 6 Bowden FJ, Harman PJ, Lucas CR. Serum trimethoprim and sulfamethoxazole levels in AIDS. *Lancet* 1986; **i**: 853.
- 7 Small CB, Harris CA, Friedland GH, Klein RS. The treatment of *Pneumocystis carinii* pneumonia in the Acquired Immunodeficiency Syndrome. *Arch Int Med* 1985; **145**: 837–840.
- 8 Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for the treatment of *Pneumocystis carinii* pneumonia in the Acquired Immunodeficiency Syndrome. A prospective, non crossover study. *Ann Int Med* 1988; **109**: 280–287.
- 9 Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for *Pneumocystis carinii* pneumonia in the Acquired Immunodeficiency Syndrome. A prospective randomised trial. *Ann Int Med* 1986; **105**: 37–44.
- 10 Medina I, Mills J, Leoung G, et al. Oral therapy for *Pneumocystis carinii* Pneumonia in the Acquired Immunodeficiency Syndrome. A controlled trial of trimethoprim sulfamethoxazole versus trimethoprim-dapsone. *New Engl J Med* 1990; **323**: 776–782.
- 11 Rieder MJ, Uetrecht J, Shear NH, Spielberg SP. Synthesis and *in vitro* toxicity of hydroxylamine metabolites of sulfonamides. *J Pharmac exp Ther* 1985; **244**: 724–728.
- 12 Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by *in vitro* 'rechallenge' with hydroxylamine metabolites. *Ann Int Med* 1989; **110**: 286–289.
- 13 Shear NH, Spielberg SP. *In vitro* evaluation of a toxic metabolite of sulfadiazine. *Can J Physiol Pharmac* 1985; **63**: 1370–1372.
- 14 Eck HP, Gmunder H, Hartman M, Petzoldt D, Volker D, Droge W. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1 infected patients. *Biol Chem Hoppe-Seyler* 1989; **370**: 101–108.
- 15 Buhl R, Jaffe HA, Holroyd KJ, et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. *Lancet* 1989; **ii**: 1294–1298.
- 16 Rieder MJ, Krause R, Bird IA, Dekaban GA. Sulfonamide toxicity in HIV infection. *Clin Pharmac Ther* 1994; **55**: 181 (Abstract OII-B-2).
- 17 Vree TB, Hekster YA. Clinical pharmacokinetics of sulfonamides and their metabolites. An encyclopedia. 1st ed. Basel: S Karger AG *Antibiot Chemother* 1987; **37**: 1–214.
- 18 Vree TB, van der Ven AJAM, Verwey-van Wissen CPWGM, et al. Isolation, identification and analysis of sulfamethoxazole and its known metabolites from human urine by high performance liquid chromatography of human plasma and urine. *J Chrom Biom Appl* 1994; **658**: 327–340.
- 19 Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. *Clin Pharmac Ther* 1992; **51**: 522–526.
- 20 Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. *Drug Metab Dispos* 1991; **19**: 900–906.

- 21 van der Ven AJAM, Mantel M, Vree TB, Koopmans PP, van der Meer JWM. Formation and elimination of sulfamethoxazole hydroxylamine after oral administration of sulphamethoxazole. *Br J clin Pharmac* 1994; **38**: 147–150.
- 22 Vree TB, van der Ven AJAM, Koopmans PP, van Ewijk-Beneken Kolmer EWJ, Verwey-van Wissen CPWGM. Pharmacokinetics of sulfamethoxazole. *Clin Drug Investigation* 1995; **9**: 43–53.
- 23 Proost JH, Meyer DKF. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. *Comput Biol Med* 1992; **3**: 155–163.

*(Received 22 June 1994,
accepted 3 February 1995)*